EDIT · Editas Medicine, Inc.
AI read · Neutral
The AI's read
The firms disagree about Editas, and neither update reports a change in the company's business. Their ratings alone give no clear reason to change its outlook.
RBC Capital says to hold Editas Medicine stock at $4, while Wells Fargo says to buy it at $6.
Neutral
RBC kept its Hold rating and $4 target, while Wells Fargo kept Buy and $6. Their views differ, and neither update reports a change in Editas's business.
Get alerts for EDIT
Follow Editas Medicine, Inc. (EDIT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EDITFree on the App Store and Google Play, or on the web.